Zobrazeno 1 - 10
of 115
pro vyhledávání: '"Hye Ryun Kim"'
Publikováno v:
Journal of Microbiology and Biotechnology.
Makgeolli is a traditional rice wine favored by the general public in Korea. This study investigated the fermentation and sensory characteristics of using wild yeast strains for brewing makgeolli. A non-Saccharomyces cerevisiae strain was isolated fr
Autor:
Hye Ryun Kim, Gamin Kim, Yong-Soo Bae, Insuk Lee, Seong Yong Park, Sang Jun Ha, Heonjong Han, Jae Won Cho, Seyeon Park, Hyo Sup Shim, Sunhye Shin
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-16 (2021)
Nature Communications
Nature Communications
Patients with non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations exhibit an unfavorable response to PD-1 inhibitor through unclear mechanisms. Hypothesizing that EGFR mutations alter tumor-immune interactions, w
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-10 (2021)
Scientific Reports
Scientific Reports
Prior diffusion tensor imaging (DTI) studies have investigated white matter (WM) changes in patients with primary restless legs syndrome (RLS), but the results were inconsistent. Here, we proposed using tract-specific statistical analysis (TSSA) to f
Autor:
Hye Ryun Kim, Min Hee Hong, Sang Jun Ha, Insuk Lee, Byoung Chul Cho, Young Joon Kim, Jae Won Cho
Publikováno v:
Experimental & Molecular Medicine
Experimental and Molecular Medicine, Vol 52, Iss 9, Pp 1550-1563 (2020)
Experimental and Molecular Medicine, Vol 52, Iss 9, Pp 1550-1563 (2020)
Although approved programmed cell death protein (PD)-1 inhibitors show durable responses, clinical benefits to these agents are only seen in one-third of patients in most cancer types. Therefore, strategies for improving the response to PD-1 inhibito
Autor:
Byoung Chul Cho, Seong Gu Heo, Young Joo Min, Keon Uk Park, Hyo Song Kim, Tae Min Kim, Min Kyoung Kim, Kyu Ryung Kim, Ik Joo Chung, Yun Gyoo Lee, Hye Ryun Kim, Min Hee Hong, Yoon Ho Ko, Hoon Gu Kim, Jinseon Yoo
Publikováno v:
Cancer. 126:4521-4531
Background The objective of the current study was to investigate the clinical activity of, safety of, and predictive biomarkers for afatinib, an irreversible pan-ErbB kinase inhibitor, in patients with recurrent and/or metastatic esophageal squamous
Autor:
Min Hwan Kim, Hyundeok Kang, Sangwoo Kim, Hojin Cho, Eun Chang Choi, Se-Heon Kim, Su Jin Heo, Young Min Park, Da Hee Kim, Jae Hwan Kim, Min Hee Hong, Sun Och Yoon, Hye Ryun Kim, Ji Min Lee, Yoon Woo Koh, Dongmin Jung, Byoung Chul Cho, Jae Woo Choi
Publikováno v:
British Journal of Cancer
Br J Cancer
Br J Cancer
Background Oropharyngeal cancer (OPC) exhibits diverse immunological properties; however, their implications for immunotherapy are unknown. Methods We analysed 37 surgically resected and nine recurrent or metastatic anti-programmed death-1 (PD-1)/pro
Autor:
Hye Ryun Kim, So Hee Park, Haengseok Song, Ji Eun Won, Ha Eun Shin, Yeon Sun Kim, Gyeong Ryeong Kim, Mira Park, Juhee Lee, Seung Chel Yang
Publikováno v:
Tissue Eng Regen Med
BACKROUND: CRISPR/Cpf1 is a class II, type V RNA-guided endonuclease that is distinct from the type II CRISPR/Cas9 nuclease, widely used for genome editing. Cpf1 is a smaller and simpler endonuclease than Cas9, overcoming some limitations of the CRIS
Autor:
Yoon Jin Cha, Inkyung Jung, Jae Hwan Kim, Chang Young Lee, Hyo Sup Shim, Kyoung Ho Pyo, Byoung Chul Cho, Hye Ryun Kim, Seong Yong Park, Min Hee Hong, Eun Ah Choe
Publikováno v:
Lung Cancer. 136:30-36
Objectives The treatment for stage III non-small cell lung cancer (NSCLC) is quite variable because stage III NSCLC is a heterogenous disease. Programmed death ligand 1 (PD-L1) and CD8+ tumor infiltrating lymphocytes (TILs) are thought to be related
Autor:
Hua Li, Patrick Kwok Shing Ng, Gordon B. Mills, Janice Cho, Danielle L. Swaney, Daniel Johnson, Gabi Tarcic, Mi-Ok Kim, Natalia Jura, Yan Zeng, Bhumsuk Keam, Michelle J. Lee, Hyunseok Kang, Zohar Barbash, Julie E. Bauman, Hayarpi Torosyan, Nevan J. Krogan, Nathan K. VanLandingham, Hye Ryun Kim, Nan Jin, Jennifer R. Grandis
Publikováno v:
The Journal of clinical investigation, vol 131, iss 22
J Clin Invest
J Clin Invest
Alpelisib selectively inhibits the p110α catalytic subunit of PI3Kα and is approved for treatment of breast cancers harboring canonical PIK3CA mutations. In head and neck squamous cell carcinoma (HNSCC), 63% of PIK3CA mutations occur at canonical h
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b8ff55fc1287790733f423737cb6d1b5
https://escholarship.org/uc/item/2mg9x9k4
https://escholarship.org/uc/item/2mg9x9k4
Publikováno v:
Cancers
Cancers, Vol 13, Iss 5365, p 5365 (2021)
Cancers, Vol 13, Iss 5365, p 5365 (2021)
Simple Summary Despite the rapid advancement in immunotherapy and targeted agents, many patients diagnosed with cancer have poor prognosis with dismal overall survival. One of the key hallmarks of cancer is the ability of cancer cells to reprogram th